Form 4: Tandem Diabetes CTO Reports Routine Stock Transactions
Insider Transaction Report
Tandem Diabetes Care's Chief Technology Officer, Rick Carpenter, reported the vesting of restricted stock units and subsequent tax-related share withholding.
Summary
- Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions involving the company's common stock.
- On September 15, 2025, 406 shares of common stock were acquired upon the vesting of Restricted Stock Units (RSUs) at an exercise price of $0.
- Concurrently, 207 shares were disposed of at a price of $12.09 to satisfy tax withholding requirements related to the RSU vesting.
- Following these transactions, Carpenter's direct beneficial ownership of common stock decreased from 22,773 shares to 22,566 shares.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction involving the vesting of restricted stock units and subsequent tax withholding. This is a standard compensation event and does not indicate a significant positive or negative shift in the company's operational or financial performance.
Positives
- The vesting of Restricted Stock Units (RSUs) indicates a component of executive compensation being realized, aligning management's interests with shareholder value over time.
Negatives
- A portion of the vested shares (207 shares) was sold to cover tax obligations, resulting in a net reduction of 207 shares in direct beneficial ownership.
Risks
- No specific risks are detailed in this Form 4 filing, as it primarily reports insider transactions.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing is a routine disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitive landscape analysis. It reflects standard executive compensation practices within the public company sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Plan Reference | The reported Restricted Stock Units (RSUs) were awarded pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and related agreements. | 12/15/2021 | Reinforces the company's existing equity compensation framework for executives, aligning their long-term interests with shareholder value. |
Stakeholder Impact
- Shareholders: Minor impact, as it's a routine compensation event. Provides transparency into executive stock ownership changes.
- Management: Realization of a portion of long-term incentive compensation.
Next Steps
- Remaining Restricted Stock Units (RSUs) will continue to vest in twelve equal quarterly installments following the initial 25% vesting on December 15, 2022.
Key Dates
| Date | Description |
|---|---|
| 12/15/2021 | Date Restricted Stock Units (RSUs) were awarded pursuant to the 2013 Stock Incentive Plan. |
| 12/15/2022 | Date of first vesting for 25% of the total RSU shares. |
| 09/15/2025 | Date of reported stock transactions (RSU vesting and tax withholding). |
| 09/16/2025 | Date the Form 4 was signed by the attorney-in-fact for Rick A. Carpenter. |
Recommendation
holdThis Form 4 filing details a routine insider transaction where the Chief Technology Officer realized vested Restricted Stock Units and subsequently sold a portion to cover tax obligations. Such a transaction is a standard part of executive compensation and does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change from a 'hold' recommendation. Investors should look to broader financial reports and company announcements for investment decisions.
Keywords
TNDM, Tandem Diabetes Care, Form 4, Insider Transaction, Rick Carpenter, Chief Technology Officer, Restricted Stock Unit, RSU Vesting, Stock Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.